Trial Profile
A Phase II Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety, Tolerability and Efficacy of RG2417 (Uridine) in the Treatment of Bipolar I Depression.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2011
Price :
$35
*
At a glance
- Drugs Uridine (Primary)
- Indications Bipolar I disorders
- Focus Therapeutic Use
- 08 Mar 2011 Top-line results from this study published in a Repligen Corporation media release.
- 08 Mar 2011 Secondary endpoint 'Clinical-Global-Impressions-scale' has not been met
- 08 Mar 2011 Primary endpoint 'Montgomery-Asberg-Depression-Rating-Scale' has not been met